Impact Therapeutics Limited, a active public limited company, was established on 29 December 2010 in Mumbai, Maharashtra, India. Engaging in api manufacturers within the trade sector, it holds CIN: U51909MH2010PLC211564. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹15.10 Cr and a paid-up capital of ₹15.10 Cr.
Formerly known as Miles Tradexim Private Limited, Impact Therapeutics Limited. It upholds a compliant status. Its leadership includes Ambarish Chatterjee (Director), Pooja Rajan Ambure (Director), Rakesh Grihpati Singh (Additional Director). Past directors included Sony Jena, Sriharsa Sri Kora Padhy, Ambarish Chatterjee. It holds ₹128.00 Cr open charges and ₹15.00 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 1004, 10Th Floor, Lodha Supremus Powai, Saki Vihar Road, Opp Mtnl Office, Powai, Mumbai, Maharashtra, 400072.
U51909MH2010PLC211564
211564
29 December 2010
₹15.10 Cr
₹15.10 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Impact Therapeutics Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ambarish Chatterjee | Director | 25 Jan 2024 | Current |
| Pooja Rajan Ambure | Director | 25 Jan 2024 | Current |
| Rakesh Grihpati Singh | Additional Director | 15 Jul 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Sep 2022 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2022 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2024 | Past |
| Pramod Abcsdd | Additional Director | 31 Dec 2020 | Past |
| Pramod Abcsdd | Additional Director | 14 Mar 2020 | Past |
| Pramod Abcsdd | Director | 06 May 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Medec Medicare Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 94.16% increase. The company also saw a substantial improvement in profitability, with a 847.61% increase in profit. The company's net worth Soared by an impressive increase of 56.68%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Impact Therapeutics had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹1,280,000,000.00
₹150,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Jun 2023 | Axis Bank Limited | ₹20.00 Cr | Open |
| 14 Feb 2023 | Axis Bank Limited | ₹20.00 Cr | Open |
| 16 Feb 2022 | Axis Bank Limited | ₹88.00 Cr | Open |
| 11 Apr 2025 | Hdfc Bank Limited | ₹15.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Impact Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Impact Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Impact Therapeutics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge registered on 11 Apr 2025 via Charge ID 101103145 with Hdfc Bank Limited was fully satisfied on 15 Nov 2025. was recorded as a recent event.
Progress on Rakesh Grihpati Singh was appointed as a Additional Director was appointed as a Additional Director on 15 Jul 2025 & has been associated with this company since 6 months 3 days . was documented.
A charge with Hdfc Bank Limited amounted to Rs. 15.00 Cr with Charge ID 101103145 was registered on 11 Apr 2025. was recorded as a recent event.
Progress on Impact Therapeutics Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
The activity Impact Therapeutics Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was completed.
The activity Ambarish Chatterjee was appointed as a Director was appointed as a Director on 25 Jan 2024 & has been associated with this company since 1 year 11 months . was completed.
The CIN of Impact Therapeutics Limited is U51909MH2010PLC211564.
Impact Therapeutics Limited is headquartered at 1004, 10Th Floor, Lodha Supremus Powai, Saki Vihar Road, Opp Mtnl Office, Powai, Mumbai, Maharashtra, 400072.
Impact Therapeutics Limited was incorporated on 29 December 2010.
The current directors of Impact Therapeutics Limited are
The primary industry of Impact Therapeutics Limited is Trade.
Impact Therapeutics Limited is unlisted.
The authorized capital of Impact Therapeutics Limited is ₹15.10 Cr, and the paid-up capital is ₹15.10 Cr.
The compliance status of Impact Therapeutics Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX